Down syndrome

Down syndrome is the most common chromosomal condition among live births. It is usually caused by an extra copy of chromosome 21, which is why it is also called trisomy 21. The condition is associated with intellectual disability, a recognizable set of physical features, and a higher risk of certain medical problems, especially congenital heart defects. Its severity varies widely from person to person, and the condition has no cure. Management focuses on health surveillance, early developmental support, and inclusion in education and society.

Down syndrome matters to medicine for several reasons. It was one of the first human conditions linked to a specific chromosomal abnormality, and it remains a central example in human genetics of how an extra chromosome changes gene expression across the genome. Its prevalence depends on maternal age and on prenatal screening practices, so it is also a major topic in epidemiology and public health. Prenatal testing has raised widely discussed questions about informed consent, counseling, and ethics, and the condition's links to early-onset Alzheimer's disease make it a subject of research on aging.

This entry begins with the clinical features and the chromosomal basis of the condition, then examines the causes and molecular mechanisms behind it. It goes on to describe physical traits, co-occurring conditions, cognitive development, and the links to Alzheimer's disease. Diagnosis, prenatal screening, history, and prevalence follow. The final sections cover medical management, education, adult life and life expectancy, research on new treatments, and the social and legal dimensions of disability rights.

Definition and recognized features

Down syndrome is a genetic condition in which the cells carry three copies of chromosome 21 instead of the usual two. Because of this extra genetic material, the condition is also called trisomy 21, a term that refers to an extra copy of a whole chromosome. Down syndrome is the set of physical, mental, and functional abnormalities that result from trisomy 21, the presence in the genome of three rather than the normal two chromosomes 21. Among genetic causes, it is the one most often linked to intellectual disability. The most common genetic cause of intellectual disability is Down syndrome (DS), trisomy 21. Some sources note that Down syndrome is by far the most common and best known chromosomal disorder in humans.

Intellectual disability is usually mild or moderate, although severe cases occur rarely. The degree of intellectual disability is usually mild or moderate but can rarely be severe.

Clinicians recognize the condition largely through a set of physical signs. In the face, these include upslanted palpebral fissures, epicanthal folds, flat facial profile, and small, low-set ears with narrow ear canals. Some people also have white speckles (Brushfield spots) may be seen on the iris. The most consistent neurological sign is reduced muscle tone. The hallmark neurologic feature of Down syndrome is hypotonia. Hands and feet often show their own patterns: fingers are short, with incurving of the fifth finger (clinodactyly) and, often, a single transverse palmar crease. Height is typically below average, and many other functionally inconsequential minor abnormalities of the ears, hands, and feet may also be present, and stature is generally reduced.

Not every sign is present in every person, and the signs are not all equally visible. Some infants show few striking traits at birth, and their facial features become more apparent during infancy. Some do not have obviously unusual physical characteristics at birth and then develop more noticeable characteristic facial features during infancy. The overall profile of abilities and health problems also varies widely. Levels of ability and challenges range widely in individuals with Down syndrome. Researchers describe this as significant heterogeneity and individual differences in cognition, language, and social and behavioral difficulties.

Why two people can differ

Even when two people share the same chromosomal diagnosis, their appearance and health can diverge considerably. Part of the explanation lies in the chromosomal form. Some people have the extra material only in a subset of cells, a pattern called mosaicism, and such individuals often show fewer features. Other sources of variation are not fully understood, since differences in the proportion of abnormal cells in different tissues cannot be measured directly in practice. Even people with Down syndrome without mosaicism can have variable clinical findings. The genetic and environmental influences behind this spread are discussed in later sections.

Why chromosome analysis confirms the diagnosis

Physical appearance alone is not reliable enough to confirm the condition, because many features are subtle, overlap with other conditions, or emerge only later. In practice, a clinician who suspects the condition after birth relies on observation first and then turns to laboratory testing. After birth, the diagnosis is suggested by the child's physical appearance and is confirmed by finding an extra chromosome 21, usually by testing a blood sample. The standard test is karyotyping, which shows the complete chromosome complement in a cell. Karyotypes detect any chromosomal aneuploidy (i.e. numerical abnormality) as well as structural chromosomal rearrangements. This matters because the same visible presentation can arise from full trisomy, a translocation, or mosaicism, and the karyotype is what distinguishes them. In many pregnancies, the question is raised earlier by prenatal screening, and the chromosome test then provides the definitive answer. The diagnosis of Down syndrome is generally made by prenatal testing, such as chorionic villus sampling or amniocentesis after a positive first or second trimester screening test.

Estimates of how often the condition is born also vary by source and place. It is a genetic disorder that occurs in approximately one of 700 births in the United States. Other compilations give a somewhat higher figure, with approximately 1 in 800 live births, with a striking increase in frequency with advanced maternal age. Differences between such figures reflect the data sources and time periods involved, and are addressed in the epidemiology section.

Chromosomal types: standard trisomy, translocation, and mosaicism

Down syndrome is not one single chromosomal arrangement. The extra material from chromosome 21 can be present in several forms, and these forms differ in how often they occur, how they pass between generations, and how much they tend to affect a person's features. Clinicians sort cases into three main groups, although rarer variants also exist.

Standard (nonmosaic) trisomy 21

Standard trisomy 21 accounts for the large majority of cases. Each cell of the body contains an extra chromosome 21, giving a total of 47 chromosomes. The usual estimate is that trisomy 21 makes up about 95% of cases. The error almost always arises during meiosis, when a pair of chromosome 21 copies fails to separate properly in a sperm or egg cell, a process known as nondisjunction. Because the extra copy is present in every cell, the features of this form are typically the most consistent across individuals.

Robertsonian translocation

In a Robertsonian translocation, two chromosomes of the acrocentric group (numbers 13, 14, 15, 21 and 22) fuse at or near their centromeres. The long arms of the two chromosomes join, and their short arms, which carry redundant ribosomal genes, are lost. When chromosome 21 is one of the partners, the person may carry an extra dose of chromosome 21 material attached to another chromosome. Estimates of this form vary by source: one reference gives about 3% of cases, while another puts the figure at approximately 4%.

The key distinction is between balanced and unbalanced forms. A parent who carries the rearrangement in a balanced form usually has no clinical signs, since the genetic material is complete. Balanced carriers are typically healthy, but meiotic segregation can produce gametes that lead to monosomic or trisomic embryos, so they face a higher chance of miscarriage or of a child with an abnormal chromosome number. Recurrence risk depends heavily on which parent is the carrier. One summary gives about 10% to 15% if the mother is the carrier and 2.5% to 5% if the father is the carrier, compared with about 1% when neither parent carries the rearrangement. Other sources cite a higher general recurrence figure for standard trisomy, so these numbers should be read with care. When both chromosomes in the rearrangement are 21 (a 21;21 translocation), the risk is far higher: for carriers of the homologous rob(21;21), there is a 100% risk of trisomy and, therefore, of Down syndrome. Most unbalanced translocation cases are not inherited, however. One summary estimates that approximately 75% of the unbalanced translocations are de novo, and approximately 25% result from familial translocation.

Mosaic Down syndrome

In mosaic Down syndrome, the individual has two or more cell populations, and only some of them carry the extra chromosome. People with Down syndrome mosaicism have two cell lines: one with the normal 46 chromosomes and one with 47 chromosomes, including an extra chromosome 21. The proportion of affected cells is usually reported as a percentage, based on counting the chromosomes in a sample of cells. The event is thought to occur after fertilization. Down syndrome mosaicism presumably results from nondisjunction during cell division in the embryo.

Estimates of its frequency also vary. One reference gives about 2% of cases, while another lists about 1% to 6% of cases. Because the proportion of normal cells differs from person to person, the features are variable. Such patients may have more subtle features, but the presentation is very variable. Milder physical signs and in some cases a less pronounced developmental profile are common, but the degree of involvement depends on which tissues contain the extra chromosome, and this is one reason mosaic cases can be missed or diagnosed late.

Partial trisomy and other rare variants

Partial trisomy 21 is a duplication of only one segment of chromosome 21, rather than the whole chromosome. Partial (segmental) trisomy 21 is the duplication of only a delimited region of Hsa21 and can be associated or not with Down syndrome. Studying these cases has been central to identifying which parts of the chromosome are responsible for specific features. An early example, a familial translocation described in 1977, suggested that trisomy of band 21q22 is pathogenetic for the phenotype of Down's syndrome.

Breakpoint mapping, which identifies exactly where a rearrangement starts and stops, has refined this picture. Earlier work described a region of approximately 5 Mb that contains 25–50 genes as a Down syndrome critical region. Later systematic reanalysis narrowed this considerably: one study of 125 cases identified a highly restricted DSCR (HR-DSCR) of only 34 kb on distal 21q22.13 has been identified as the minimal region whose duplication is shared by all DS subjects and is absent in all non-DS subjects. Other partial trisomy cases show that the same segment does not always produce the full syndrome. Subjects with partial trisomy 21 can be classified as having a Down syndrome diagnosis or not having one. Cases with complex rearrangements also illustrate how other genomic changes can modify the phenotype. One adult with a duplication of distal 21q and a deletion on chromosome 7 presented with only mild clinical symptoms.

Because breakpoints determine which genes are duplicated, and whether additional imbalances are present, two people with apparently similar rearrangements can show different features. This is one reason that precise breakpoint analysis matters for both explaining phenotypes and advising families.

Origins and risk factors

In most people with Down syndrome, the extra chromosome 21 comes from nondisjunction, a failure of paired chromosomes to separate normally during meiosis in the parental germ cells. One review estimates that approximately 95% of Down syndrome cases result from sporadic nondisjunction during parental meiosis, with 95% of these being maternal in origin. Other analyses put the maternal share somewhat lower, at around 88 to 94 percent, so the exact figure depends on the cohort and method. Within maternal errors, approximately 75% are considered errors in meiosis I and 25% as errors in meiosis II. Paternal errors account for only about a tenth of cases.

Maternal age is the strongest established risk factor. Using commonly cited figures, the incidence is about 1 in 1,250 for mothers at age 25 rising to 1 in 100 for those at age 40. The explanation lies in the long life of the egg. A female oocyte stays arrested in meiosis for years, from fetal life until ovulation, which makes its chromosome pairing more fragile than sperm development, where the process is continuous. The risk of nondisjunction increases gradually with age, which is attributed to the breakdown of protein machinery, including the sister chromatid cohesins that hold chromatids together. Genetic analyses also suggest that the age effect is concentrated in maternal cases rather than being a general selection against trisomic pregnancies in older women.

A second, related mechanism is altered recombination. Crossovers between homologous chromosomes help hold pairs together and guide them apart. Aside from maternal age, the only single factor that has been identified unambiguously with maternal nondisjunction is an altered pattern of meiotic recombination. Some studies have linked variants in genes such as MCM9, which is involved in recombination, to a higher chance of recombination failure on chromosome 21, especially in older mothers. Evidence for a grandmother-age effect exists but is less established.

Translocation cases follow different rules. In a Robertsonian translocation, the long arms of two acrocentric chromosomes (13, 14, 15, 21, or 22) are fused, with loss of their short arms. A parent who carries such a rearrangement in balanced form is usually healthy, but because meiotic segregation results in nullisomic or disomic gametes, they have an increased risk of miscarriage or offspring with aneuploidy. Recurrence risk depends mainly on which parent carries the translocation. If the mother is a rob(14q21q) carrier, the risk of recurrence is 10% to 15%. If the father is a rob(14q21q) carrier, the risk of recurrence is less than 5%. Some sources give lower paternal figures, so these numbers should be read as approximate. When both parents have a 21;21 translocation, recurrence is near-certain. By contrast, the observed recurrence risk in a series of translocation cases was less than 1% when both parents have normal karyotypes and the rearrangement appears to be new. For such translocations the maternal age of the carrier is not a major factor, and the recurrence risk for standard trisomy is generally low.

No single environmental exposure has been shown to cause Down syndrome. Several factors have been studied, including maternal cigarette smoking, use of oral contraceptive, peri-conceptional alcohol consumption by mother, exposure to radiation and low socio-economic status. However, the evidence of association of those factors with DS has not been consistent. A 1950s hypothesis linking water fluoridation to more cases has not been confirmed. Some researchers have also looked at folate-metabolism genes, and genetic polymorphisms were associated with a higher rate of chromosomal nondisjunction, particularly in the genes for folate metabolism, although these findings are not yet established. Public health bodies have stated that no definitive environmental or behavioral cause has been identified. Current knowledge has clear limits: most studies are observational, sample sizes are often small, and interactions with maternal age complicate the picture. Some reviewers consider it likely that environmental influences exist, but none has been proven to act independently of maternal age.

Molecular mechanisms and gene dosage

Down syndrome is widely described as a gene dosage disorder. Chromosome 21 carries roughly 230 protein-coding genes, and a third copy of some of them raises the amount of their products in cells. The working model is that this imbalance, spread across many pathways, produces the physical and cognitive features of the condition. The model is supported by data but has not been fully tested. The question of which genes matter most is still open.

The gene dosage model

The most common explanation is that the extra chromosome 21 causes overexpression of genes located on it, which disturbs the balance of their protein products. Studies of individual genes, such as SOD1 and DYRK1A, have shown that their expression is elevated in trisomic cells. Partial trisomy and microduplication cases give a further test. A boy with a mosaic duplication of part of 21q22 showed a Down syndrome phenotype, and the only duplicated candidate gene in his case was DYRK1A. This supports a role for that gene even when the extra copy is present in only some cells. Conversely, a deletion that removes one copy of DYRK1A and nearby genes has been linked to severe microcephaly, which suggests that the normal dosage of the gene matters in both directions.

Candidate genes and the critical region

Researchers have tried to narrow the genetic basis of the condition by mapping the Down syndrome critical region (DSCR) on the long arm of chromosome 21, in the band 21q22. Mapping studies in people with partial trisomies suggested that duplication of a segment in this region is enough to produce many classic features, while duplications of segments outside it are not associated with the same phenotype. Among the genes proposed as candidates for key clinical features are APP, DSCR1 (also called RCAN1), DYRK1A, and DSCAM. DYRK1A encodes a protein kinase that phosphorylates serine, threonine, and tyrosine residues, and it interacts with proteins involved in the cytoskeleton, synapses, and transcription. Mouse studies show that its dosage is important for normal brain development. A recent preprint, which has not yet been widely replicated, reports that increased DYRK1A dosage is needed to produce heart defects in mouse models. DSCAM, which encodes an adhesion molecule involved in neural development, is among the better-known signaling genes in the region.

Genome-wide and epigenetic effects

The effects of trisomy 21 are not limited to chromosome 21. Studies of neonatal blood samples have shown changes in DNA methylation across the genome. One such study compared 196 newborns with Down syndrome with 439 without it and found 652 CpG sites with significant methylation differences, with the strongest differences near genes such as RUNX1 and FLI1, which regulate blood cell development. Comparisons of monozygotic twins discordant for trisomy 21 also suggest that the extra chromosome changes the methylation status of loci elsewhere in the genome. Chromatin studies point in the same direction. Trisomy 21 cells show altered histone marks and chromatin accessibility at many genes, including neurogenic genes.

Gene expression data show that the effect is more selective than a simple sum of extra genes. Some analyses report that the overall transcriptome changes only modestly, even though epigenomic changes are widespread. Other work has described a broader amplification of transcription that is linked to the overexpression of HMGN1, a chromatin-associated protein on chromosome 21. Experiments that silence the extra chromosome in cell models, using XIST, show that dosage compensation affects most of the overexpressed genes on chromosome 21, while a smaller set of genes elsewhere in the genome changes in a consistent way. Overall, the extra chromosome seems to act through networks that influence one another, rather than through a list of independent gene effects.

Why no single gene explains the syndrome

The clinical picture involves heart, brain, immune, skeletal, and blood-forming systems, and the individual genes that have been studied each explain only part of it. Their effects also depend on the cell type, developmental stage, and genetic background, and they interact with other genes and with chromatin state. Individual differences are large even among people with the same karyotype, and comparisons of monozygotic twins show that epigenetic and other variability contributes to this. For these reasons, most researchers now treat the phenotype as an outcome of many dosage-sensitive genes acting together, with the exact combination still unresolved.

Physical characteristics and congenital anomalies

Many people with Down syndrome share a recognizable set of physical traits, but no single feature appears in everyone, and their severity varies widely. The face is the most frequently described area. The eyes slant upward, epicanthal folds at the inner corners are common, the nasal bridge is flat, and the nose and mouth are small, while the tongue can look large for the oral cavity. The ears may be small, low-set, or have an overfolded upper rim. The skull tends to be short and broad (brachycephaly), with a sloping forehead, a flattened back of the skull, and fontanelles that close late. Anatomical descriptions also note underdeveloped paranasal sinuses, including frontal and sphenoid sinuses that may be absent, which contributes to the flattened midface. These differences reflect altered growth of the skull and face during fetal development, a process that the extra copy of chromosome 21 is thought to influence. The mechanisms are discussed in the molecular section.

Hypotonia, or reduced muscle tone, is one of the most consistent features. Newborns are often placid, rarely cry, and respond weakly to stimulation. Joint laxity and hypermobility are also very common. Joint laxity is considered nearly universal in children with the condition, and together with hypotonia it delays motor milestones and reduces physical activity. Children usually reach the same milestones as other children, but they often turn over, sit, stand, and walk later. Growth is typically slow, and short stature is characteristic. Excessive ligament laxity has been linked to altered production of type VI collagen, whose gene lies on chromosome 21, although this remains a proposed explanation rather than a settled one. The orthopedic consequences, such as cervical instability and hip or patellar problems, are covered in other sections.

Congenital heart defects are among the most important physical associations. Estimates vary by population: one review reports them in more than 40% of infants with the condition, while a Korean series found them in 57%. Septal defects make up most cases. Atrioventricular septal defect (AVSD) occurs far more often in people with Down syndrome than in the general population, with a prevalence reported to be more than 2000 times higher. Its frequency depends strongly on region. In North American and European series, it is the most common defect, accounting for roughly 40–70% of cardiac malformations in some reports. In a Mexican cohort, by contrast, AVSD accounted for only about 8.7% of cases, and patent ductus arteriosus, ventricular septal defect, and atrial septal defect predominated. Among AVSD cases, the complete form is the most frequent. Heart defects are a major cause of illness and death in infancy, which is why echocardiography is typically performed early, and surgery is often timed according to the defect's severity.

Gastrointestinal anomalies are also clinically significant in the newborn period. Duodenal atresia or stenosis is among the most common, with one large US cohort reporting it in about 3.9% of infants with the condition. This is far above the general rate of roughly 1 in 10,000 live births. It typically presents with vomiting, abdominal distension, and a "double-bubble" pattern on abdominal X-ray, and it may be suspected before birth because of excess amniotic fluid. Duodenal atresia is a neonatal emergency that generally requires surgical repair. Hirschsprung disease, in which nerve cells are absent from the distal bowel, produces functional obstruction and may present as failure to pass meconium or persistent constipation. Reported frequencies differ: about 0.8% in the same US cohort, but estimates of roughly 1 in 40 in some other studies, compared with about 1 in 5000 in the general population. Because both conditions can coexist and overlap in their early signs, a neonate with suspected intestinal obstruction needs careful evaluation, and the co-occurrence is sometimes discovered only during surgery.

Several skeletal and skin features help clinicians recognize the condition. The hands are often short and broad, the fifth finger is short and curved (clinodactyly), and a single transverse palmar crease appears in about 60% of patients. A wide gap between the first and second toes, known as the sandal gap, is typical. Other common findings include a shallow acetabular angle, diastasis recti, a short neck with redundant skin at the back, and dry skin. Brushfield spots, small white or grey speckles on the iris, are also described. None of these signs is diagnostic on its own, and features vary greatly between individuals, so they prompt chromosomal testing rather than replace it.

Co-occurring medical conditions

People with Down syndrome have a higher-than-average risk of several conditions that are not part of the chromosomal change itself. Many of them can be detected early and treated if they are monitored over time. Reported frequencies vary by study, age group, and screening method, so the figures below are approximate.

Thyroid and autoimmune disorders

Thyroid dysfunction is one of the most consequential co-occurring conditions. Thyroid disease is reported in roughly 24% to 50% of people with Down syndrome, and autoimmune thyroiditis, including Hashimoto thyroiditis, is also common, with frequency depending on age. The risk of hypothyroidism rises with age, which is why guidelines recommend a yearly thyroid-stimulating hormone (TSH) test in children and adults. Many children with Down syndrome have mildly elevated TSH with normal free thyroxine levels, so interpreting results requires care. Symptoms such as dry skin can overlap with features of the syndrome itself, and in adults undiagnosed hypothyroidism can contribute to dementia or be misdiagnosed as dementia.

Hearing and ear disease

Hearing problems are very common. One guideline puts hearing loss at about 75% and otitis media at 50% to 70% in children. Middle-ear fluid is the main cause of the conductive loss seen in childhood, and narrow ear canals can favor wax buildup. Sensorineural hearing loss also occurs more often than in the general population. Because hearing loss can affect vocabulary, speech, and classroom learning, early audiological testing matters. In adults, conductive and sensorineural hearing losses occur in up to 70 percent of persons with Down syndrome, and difficulty may not appear until early adulthood, when people with limited communication skills may be unable to report it.

Vision

Eye problems are also frequent, with one review listing eye problems (60%–80%). Strabismus, cataracts, nasolacrimal duct obstruction, refractive errors, glaucoma, and nystagmus are all described. Guidelines advise that infants be seen by an ophthalmologist experienced with children with disabilities within the first six months. Keratoconus, a thinning and conical distortion of the cornea, is also more common in this population and can worsen refractive problems, so ongoing assessment is needed beyond infancy.

Obstructive sleep apnea

Obstructive sleep apnea (OSA) is common, affecting an estimated 50%–79% of children and a similar proportion of adults in some series. Reduced muscle tone in the airway, a narrow upper airway, and enlarged tonsils and adenoids contribute to it, and obstructive sleep apnea becomes more common than in the general population as children grow. Untreated sleep-disordered breathing can affect attention, daytime behavior, and learning, so clinicians are advised to evaluate for it when behavior changes. Surgical removal of tonsils and adenoids helps a substantial minority of patients, and the choice of who benefits remains a matter of clinical judgment.

Atlantoaxial instability

Atlantoaxial instability (AAI) is excess movement between the first and second cervical vertebrae. Most series estimate that approximately 10%–30% of individuals with trisomy 21 show radiologic evidence of AAI, but symptomatic disease occurs in approximately 1%–2% of affected individuals. The mechanism involves a combination of low muscle tone, loose ligaments and bony changes. Warning signs include changes in walking, weakness, loss of bladder or bowel control, and persistent head tilt, and torticollis should raise strong suspicion for atlantoaxial instability until proven otherwise. Because the cervical spine can be compressed, decisions about sports and surgery depend on careful imaging and assessment.

Celiac disease

Celiac disease occurs more often than in the general population. Pediatric guidance cites a frequency of 1%–5%, while an adult review reports that coeliac disease [occurs] in one of five in its adult cohort, a discrepancy that likely reflects differences in populations and diagnostic methods. Celiac disease can present as poor growth, altered bowel habits, or changes in behavior, so clinicians are advised to consider it when such symptoms appear.

Leukemia and transient abnormal myelopoiesis

Children with Down syndrome have a markedly increased risk of acute leukemia, particularly of the myeloid type. A distinctive feature is transient abnormal myelopoiesis (TAM), a preleukemic condition that is unique to infants with DS or mosaic trisomy 21. Estimates of how many newborns are affected range from about 5–10% of neonates with DS to around 10% in other series. Most TAM cases resolve on their own, and in one study blasts disappear spontaneously after 4 weeks in around 80% of children. However, a minority of infants develop severe liver or organ dysfunction, and some later progress to leukemia. Despite its typical transient nature, 20% to 30% of DS-TL patients develop overt (nontransient) acute leukemia, usually within 3 years. Most TAM cases are associated with acquired mutations in the GATA1 gene, a hematopoietic transcription factor on the X chromosome, which is why genetic testing for these mutations is used in newborn evaluation. Overall, later leukemia (1%) is reported in children with the syndrome.

Cognitive and developmental profile

Intellectual disability and its assessment

Intellectual disability is one of the most common features of the syndrome, but its severity ranges from mild to severe. On average, adults with Down syndrome reach a level of cognitive functioning roughly comparable to that of children aged five to eight, yet this average hides wide variation between individuals. Cognitive skills in Down syndrome develop more slowly than in the general population, as is true of intellectual disability in general. This creates a measurement problem. Standard IQ scores compare a person with age-based population norms, so a child whose development is slower than typical will receive progressively lower scores as they get older. Scores at the lowest possible value, known as floor effects, add further difficulty. For these reasons, researchers have argued that common assessment tools may obscure real differences in a person's strengths and weaknesses, and that the traditional description of the profile needs revisiting. Clinicians therefore tend to rely on several measures, including language sampling and adaptive behavior rating scales, rather than a single number.

A distinctive but variable profile

Down syndrome is associated with a cognitive pattern that is more specific than general intellectual disability. Compared with a person's overall cognitive level, relative strengths often include receptive language (understanding speech), visuospatial processing, nonverbal communication, and some aspects of social functioning. Relative weaknesses most consistently include expressive language, particularly grammar and sentence structure, and verbal short-term memory, especially auditory short-term memory. Episodic memory, executive function and visuospatial construction are also frequently described as challenging, although the evidence for some of these is mixed.

Language is one of the best-studied areas. A 2011 meta-analysis compared children with Down syndrome with typically developing children matched for nonverbal mental age. Receptive vocabulary was similar between the groups, but the children with Down syndrome performed worse on expressive vocabulary, receptive grammar and verbal short-term memory, which led the authors to describe broad language deficits rather than an expressive problem alone. The visuospatial strength is also less uniform than once assumed. Some studies find that specific visuospatial abilities, such as recalling locations or mentally rotating objects, are weaker, and that performance depends on task demands. Memory results can also depend on how memory is tested: in one comparison, adults with Down syndrome were more impaired than peers on laboratory long-term memory tasks, but not on everyday memory items such as recalling a phone number or a bedtime routine.

The profile is not fixed from birth. A longitudinal study of the first five years of life found that children's development diverged gradually from typical trajectories, and that the pattern became clearer over time. Gross motor difficulties persisted, expressive language became a more evident relative weakness, and receptive language emerged as a relative strength. Early in childhood, groups with and without Down syndrome may not differ clearly on standardized tests, which suggests that the characteristic profile is still forming.

Motor development, speech and adaptive behavior

Motor and speech development strongly shape daily life. Gross motor skills are typically delayed, and speech difficulties, including reduced intelligibility, are common alongside expressive language problems. Adaptive behavior, which covers communication, daily living and social skills, is the area most directly tied to independence. In a study of 80 children aged one to 11.5 years, parents rated communication as weaker than daily living and socialization skills. Another study of children, adolescents and young adults found that expressive language skills were significantly associated with adaptive behavior, and that several of these links remained after controlling for nonverbal cognitive ability. Language therefore appears to contribute to everyday functioning beyond what overall cognitive level would predict.

Behavioral and mental health conditions

Several neurodevelopmental and psychiatric conditions occur more often in Down syndrome, although the reported figures vary considerably. In a population-based study of 41 children, 42% met diagnostic criteria for autism spectrum disorder and 34% met criteria for ADHD. A pooled analysis of other studies reported weighted prevalences of about 5.8% for autism and 12.4% for ADHD, both significantly higher than in children without Down syndrome. Differences between studies are usually attributed to sample size, inclusion criteria, diagnostic methods and study design. Anxiety disorders are also reported to be more common, with one systematic review estimating a prevalence about 2.3 times that of the general population, though the evidence base for anxiety symptoms is thinner than for ADHD or autism. A large adult cohort found higher standardized rates of dementia, autism, ADHD and depression than in the general population, with the difference in autism being especially pronounced in women. An advocacy organization reports that at least half of children and adults with Down syndrome will face a major mental health concern during their lives, a figure that should be read as an estimate from a non-research source.

Clinical recognition is difficult. Autistic features can overlap with the symptoms of mental illness, and ADHD may be overlooked, which can leave an individual with considerable problems in engaging in activities and forming relationships.

Limits of assessment and the need for individualized evaluation

The Down syndrome profile is best understood as a group-level pattern rather than a template for any single person. Individuals differ widely in severity and in the shape of their strengths and weaknesses, and many standard tools were developed for the general population. Assessment therefore depends on combining cognitive testing, language and memory evaluation, adaptive behavior measures, and observation across home and school settings. Interpreting results requires attention to age norms, floor effects and the person's own communication abilities, so that support plans reflect what each person can actually do.

Alzheimer's disease and aging

Adults with Down syndrome develop Alzheimer's disease pathology far earlier than most people, and the explanation starts on chromosome 21 itself. The gene for the amyloid precursor protein (APP) lies on the long arm of this chromosome, at 21q21. Chromosomal triplication invariably includes the APP gene (21q21) that encodes the amyloid precursor protein. Cleavage of APP yields the amyloid-β peptides that build up as plaques in the brains of people with Alzheimer's disease. Because the extra chromosome supplies a third copy of the gene, cells make more APP, and more of the amyloid-β peptide is produced and deposited. Researchers therefore regard APP dosage as a central, though not the only, driver of the condition.

Neuropathology from early adulthood onward

The brain changes begin long before any symptoms. Autopsy studies have demonstrated that by the age of 40 years, virtually all individuals with DS exhibit SPs in their brains, and a PET study using a plaque-binding tracer found abnormal signal from about age 39, first in the striatum and then spreading to frontal, parietal, temporal and medial temporal regions. Tau pathology also accumulates early, and individuals with DS also face abnormal accumulation of phosphorylated tau in the early stage of life.

The earliest changes may be intraneuronal rather than extracellular. In a histological study, the earliest observable neuropathologic feature in DS may be neuronal accumulation of amyloid-β. Such accumulation of amyloid-β occurs decades in advance of deposition as SP, which in turn occurs decades before cognitive decline. Because the extra gene dose is present from conception, this process starts in childhood and advances gradually through adult life, which is why pathology is found across the lifespan rather than appearing abruptly in middle age. Tissue from very young individuals has shown the highest levels of neuronal amyloid-β in one small series, and the number of such neurons fell in young adults before plaques became abundant.

Onset of dementia and individual risk

Clinical dementia usually emerges later than the pathology. The average age when symptoms start is the early to mid-50s. One review estimates the mean age of onset of clinical dementia is approximately 55 years, and a widely cited set of estimates puts the cumulative risk at roughly 23% by age 50, 45% by age 55, and 88% or more by age 65. Dementia has become the leading cause of death in this population, a shift linked to longer life expectancy, which has risen from much lower levels earlier in the twentieth century.

Age at onset is highly variable, and APP dosage alone does not account for this variation. There is a wide variation in the age at onset of dementia in people with Down's syndrome and this does not appear to be solely attributable to overexpression of amyloid precursor protein. Experimental work in mice has shown that additional copies of other chromosome 21 genes can modify amyloid-β accumulation independently of APP copy number, and a genetic mapping study suggested that a relatively small set of genes is sufficient for this effect. Environmental influences and other host factors are also thought to shape timing and severity.

Diagnostic difficulties

Recognizing dementia in adults with Down syndrome is hard for several reasons. Baseline intellectual disability complicates interpretation, because the exacerbation of cognitive deficits and maladaptive behaviours that pre-date the dementia can make the onset of decline difficult to identify. Communication limits may mean that people may not present their symptoms verbally, because of their impaired communication skills. Standard tests are typically normed on people without Down syndrome, and there is no single, standard cognitive assessment used for early-stage dementia in patients with DS. Clinicians are therefore encouraged to document baseline intellectual, behavioral and social function, with one guideline suggesting this be done by age 35, so that later change can be compared with a known starting point. Early signs reported in the literature include visual memory decline, diminished learning capacity, and reduced social functioning. Imaging and fluid markers have shown promise, with one review noting good diagnostic performances and a strikingly similar temporality of changes with respect to sporadic and autosomal dominant Alzheimer's disease.

Open questions

Research continues on how much of the risk reflects the APP copy number and how much reflects other chromosome 21 genes or other genetic and environmental factors. The amyloid cascade hypothesis remains the dominant framework, but the variability in onset means it is generally seen as incomplete for this population. These questions bear directly on the design of preventive trials, which must begin well before symptoms appear, and on whether anti-amyloid therapies tested in other populations can be applied to people with Down syndrome.

Diagnostic testing after birth

Clinical suspicion and newborn recognition

Most infants are first flagged at the bedside. Down syndrome is usually identified soon after birth by a characteristic pattern of dysmorphic features. Because there is no single physical feature that is 100% specific for Down syndrome and genetic testing is needed to confirm the diagnosis. The core features that guide this examination are described in the clinical-features section.

Population newborn screening works differently. This is called newborn screening. Here, a small blood sample is collected from newborn infants within 24 hours of birth and tested for a panel of disorders. In most programmes this panel is not built to detect trisomy 21 directly, so the condition usually comes to light through examination and is then confirmed separately.

Karyotype as the confirmatory test

Clinical suspicion is verified with a karyotype analysis. Clinical diagnosis should be confirmed with a genetic test, such as a karyotype performed on a blood sample. Postnatal testing generally uses blood, since the sample types for chromosomal analysis commonly include peripheral whole blood in newborns. A karyotype displays the complete chromosome complement in a cell, so it reveals both numerical abnormality and structural rearrangements. This breadth matters because it reliably identifies Trisomy 21 and detects Robertsonian translocations, and in the majority of patients presenting with a typical phenotype, karyotyping alone is sufficient. The same test is also what separates standard trisomy from translocation and mosaic forms, which together account for a small minority of cases.

FISH and chromosomal microarray

Fluorescence in situ hybridization (FISH) is the main faster alternative. It uses fluorescent probes that attach to chosen DNA regions, and diagnostic FISH for Down syndrome would involve the use of labeled probes with sequences complementary to regions spanning chromosome 21. The presence of three labeled chromosomes would therefore be diagnostic of Down syndrome. In urgent cases, a probe aimed at the Down syndrome critical region can be processed in about two days, when an urgent result is required. Because such rapid methods do not reliably capture translocations or mosaic forms, these investigations should always be followed by a full karyotype.

Chromosomal microarray is the third complementary method. It is able to detect deletions and duplications on a submicroscopic level and has replaced conventional karyotyping in many countries; however, karyotyping is still the test of choice when aneuploidy is suspected. Microarray can also use a cheek swab, which is less invasive, but that sample cannot be used for FISH and results can take longer. FISH cannot be performed on this sample and a result usually takes 2-4 weeks and so is not recommended for urgent results. Neither method sees everything: submicroscopic copy number variants and point mutations fall entirely outside its scope. A normal karyotype result, therefore, does not rule out the presence of additional genetic contributors.

Mosaicism testing and tissue sampling

Mosaicism is the main diagnostic pitfall. Typically, 20 to 25 cells are examined. If some of the cells have trisomy 21 and some don't, then the diagnosis of mosaicism is made. However, this blood test can only determine the level of mosaicism in the blood cell line. The proportion of trisomic cells can vary among tissue types. For example, there may be differences in the percentage of trisomic cells in the blood compared to the skin, heart or other organs. The blood percentage also has limited prognostic value, since studies have consistently shown that the percentage of mosaicism found in a blood test is not an accurate predictor of IQ, heart defects, or other outcomes.

A case report illustrates the problem. In a newborn whose prenatal screening had been negative, postnatal karyotyping of phytohemagglutinin-stimulated lymphocytes confirmed trisomy 21 in all analyzed metaphases. However, fluorescence in situ hybridization on unstimulated lymphocyte nuclei and buccal smears revealed mosaicism, with approximately 20% of cells from both tissues displaying disomy for chromosome 21. The authors also noted that the detection of the full-form aneuploidy or a normal karyotype by karyotyping on PHA-stimulated lymphocytes does not rule out the possibility of mosaicism in other tissues. For this reason, when mosaicism is suspected but blood results are unclear, a skin biopsy may be ordered. Skin cells (fibroblasts) develop from a different embryonic tissue layer than blood cells (lymphocytes), so testing both tissues gives a more complete picture of the chromosomal makeup across the body. Guidance from the International Mosaic Down Syndrome Association advises complementing conventional T lymphocyte karyotyping by fluorescence in situ hybridization (FISH) or chromosomal microarray in patients who present with clinical features of the condition but have a normal karyotype.

Genetic counseling after diagnosis

Once the diagnosis is confirmed, genetic counseling explains what the result means for the child and for future pregnancies. Recurrence risk depends on the type of chromosomal change. Chromosomal abnormalities are typically sporadic; however, they can be associated with chromosome rearrangements inherited through a family. The risk is also shaped by family history: the risk of trisomy 21 increases with advanced maternal age, when an abnormal parental karyotype is present and with history of having another child or previous pregnancy with Down syndrome.

In general terms, standard trisomy 21 is usually a chance event with only a modest increase in recurrence risk, whereas a Robertsonian translocation may be inherited from a parent who carries a balanced rearrangement. For that reason, counselors typically recommend karyotyping of both parents and, where relevant, other relatives. The counseling process also covers the meaning of a mosaic result, the limits of predicting severity from a blood percentage, and the prenatal testing options available in later pregnancies.

Prenatal screening, decision-making, and ethical debates

Screening pathways

Prenatal screening estimates the probability that a fetus has trisomy 21 before any definitive test is done. Screening has moved through several generations. Early programs relied on maternal age alone, and later ones added maternal serum markers and ultrasound measurements, each intended to raise detection while keeping false positives low. Among the older options, first-trimester screening (about 10 to 13 weeks) combines a maternal blood test for pregnancy-associated plasma protein A and free beta-hCG with ultrasound measurement of nuchal translucency, adjusted for maternal age. Its detection rate for Down syndrome is commonly quoted at roughly 85%. Second-trimester serum screening, usually performed around 15 to 20 weeks, detects a smaller share of cases, around 80% in common summaries. Integrated, sequential, and contingent protocols combine markers from both trimesters to improve the balance between detection and false positives.

Cell-free DNA screening

Since the early 2010s, screening has increasingly relied on cell-free DNA (cfDNA) analysis, sometimes called noninvasive prenatal screening or testing. Fragments of placental DNA circulate in the maternal blood, and an excess of material from chromosome 21 suggests trisomy 21. The test can be done from about 10 weeks of gestation and needs only a blood sample. Early validation studies reported detection rates above 99%, but later meta-analyses of more varied populations report lower figures; one pooled estimate for Down syndrome sensitivity was about 96%, with specificity near 99.9%. A 2014 multicenter cohort found a false-positive rate of 0.06% for cfDNA, compared with 5.4% for standard serum and ultrasound screening in the same setting. Performance is lower for trisomies 13 and 18 and for sex chromosome disorders, and the test can fail to yield a result, usually because of low fetal DNA fraction; repeat sampling resolves most of these cases.

Because screening identifies risk rather than fact, a positive result requires confirmation by chorionic villus sampling (CVS) or amniocentesis, which analyze fetal karyotype. Both are invasive and carry a small risk of miscarriage. The positive predictive value of a screen depends strongly on the prevalence in the tested population; in lower-risk groups, a substantial share of positive results can be false, which is why confirmatory testing is standard.

Counseling and the period after a positive screen

Professional guidelines emphasize that the screening result is probabilistic and that families should receive information about what the test can and cannot show, including the range of outcomes associated with Down syndrome. Pre-test and post-test counseling, often delivered by genetic counselors, obstetricians, or midwives, are intended to support informed consent. In practice, the time available to make decisions is often short, and the content and quality of counseling vary considerably between services and countries. Some studies have reported that couples decide on termination before receiving confirmatory results, which raises questions about how and when information is given.

Termination rates and their interpretation

Termination rates after a prenatal diagnosis of Down syndrome are among the most cited figures in this area, but they differ markedly across countries and periods. Denmark, which has a first-trimester screening program with uptake above 90%, reports termination rates above 95% after a diagnosis. Iceland and Denmark are often cited as having near-complete termination after prenatal diagnosis, while estimates for Australia and the United Kingdom are around 90%, and US estimates range from about 67% to 85%. A 2004 European survey found wide variation in both detection and termination, with the highest proportions of prenatal detection in countries that had first-trimester screening policies, and it also noted that legal gestational limits and national policies shape outcomes. Where termination is prohibited, as in Malta, prenatal detection does not lead to termination. Live-birth prevalence has declined in several countries as prenatal diagnosis and termination have become more common, while the total number of women giving birth to affected children has not fallen to the same extent, because of rising maternal age. Figures also depend on how data are collected and on whether they cover screening uptake, diagnosis, or outcomes.

Ethical debates

Debates over prenatal screening involve several positions. Supporters emphasize reproductive autonomy, the right of parents to make informed decisions, and the value of accurate information. Critics, including some disability advocates and some bioethicists, argue that widespread screening and high termination rates may convey a message that lives with Down syndrome are less valued, and that the social and institutional support available to families is insufficient to make choices truly free. Concerns have also been raised about whether counseling is nondirective and whether the framing of screening, which is often presented as a routine part of antenatal care, leaves enough room for an informed refusal. These debates connect to questions of ethics, informed consent, and the rights of people with disabilities, and they remain unresolved in most countries.

History of discovery and naming

Retrospective identifications have been proposed for much older material, such as a terra-cotta head from the Tolteca culture of Mexico that some researchers read as showing the facial features of the condition (Martinez-Frias identified the syndrome in a terra-cotta head from the Tolteca culture of Mexico). The modern clinical description, however, is usually credited to the English physician John Langdon Down. In 1862 he presented the condition as a distinct form of intellectual impairment, and in 1866 he published a wider report, "Observations on an ethnic classification of idiots" (English physician John Langdon Down first characterized Down syndrome as a distinct form of mental retardation in 1862, and in a more widely published report in 1866). At the time, "idiocy" was a clinical label for severe intellectual impairment (Idiocy was a medical term used at that time to refer to a severe degree of intellectual impairment.).

Down's explanation for the physical resemblance was rooted in the racial theories of his era. He linked the faces of these children to the populations that Johann Friedrich Blumenbach had grouped as a "Mongolian" race, and he therefore adopted the labels "mongolism" and "mongolian idiocy" (Due to his perception that children with Down syndrome shared physical facial similarities (epicanthal folds) with those of Blumenbach's Mongolian race, Down used the terms mongolism and mongolian idiocy.). He also interpreted the traits as a kind of reversion, arguing that they reflected a throwback in children of supposedly more advanced parents (Down wrote that monoglism represented "retrogression," the appearance of Mongoloid traits in the children of allegedly more advanced Caucasian parents.). Down's son Reginald later challenged this view, arguing in 1906 that the resemblances were superficial and not evidence of racial reversion (his elder son Reginald, also studied mongolian defectives, including their palmar lines, and subsequently corrected his father's interpretation of this syndrome in 1906).

The label spread widely, and Down syndrome was also known as "Mongolism" and people with Down syndrome referred to as "Mongoloids". Although the term was recognized as racist, it remained in colloquial use into the late twentieth century (Down's original terminology, later recognised as racist, continued to be used colloquially into the late 20th century.). Today the term is regarded as misleading and offensive, and the eponymous name "Down syndrome" has replaced it in clinical and public usage (Today, it is perceived as misleading and offensive to use the term of mongoloid to refer to people with Down's syndrome.).

The cause remained unknown for nearly a century after Down's account. A 1950 chromosome study by Penrose on testicular tissue from affected men concluded that neither triploidy nor aneuploidy was responsible, a conclusion later shown to be mistaken (In 1950, a study of chromosomes on a testicular sample taken from patients with Trisomy 21 was undertaken by Penrose. The conclusion was that neither triploidy nor aneuploidy was the cause.). The exact human chromosome number was established only in 1956, which provided the framework for the 1959 discovery (With the discovery of karyotyping techniques, and the assignment, in 1956, of the exact chromosome number in humans Lejeune et al. were able to show, in 1959, that Trisomy 21 resulted from an additional chromosome.).

The key finding came from Jérôme Lejeune and his colleagues in Paris. According to the Institut Lejeune, the extra chromosome was first observed in July 1958 while Lejeune was examining the chromosomes of a child with "mongolism" (In July 1958, during an examination of the chromosomes of a child with "mongolism", he discovered the existence of an extra chromosome 21.). The work was published on 26 January 1959 with Marthe Gautier and Raymond Turpin (Lejeune and his colleagues, Turpin and Gautier, published their discovery of that link in the journal of the Académie des Sciences (Academy of Sciences) on 26 January 1959.). Gautier had seen an extra chromosome in the karyotype but could not identify which one under her microscope, and she passed the slides to Lejeune, whose better equipment allowed the identification (Gautier discovered that the karyotype from the Down syndrome patient contained an extra chromosome, but she was unable to establish which chromosome was involved using her microscope. She entrusted the slides to Dr. Jérôme Lejeune, who established the karyotype using a higher quality photomicroscope). Gautier later criticized the portrayal of Lejeune as the sole discoverer (Gautier has criticized the portrayal of Lejeune as the sole discoverer of trisomy 21.).

The discovery changed diagnosis and research. Independent confirmation followed within months, and a team in England corroborated the result in April 1959 (In April 1959, the English team of Brown and Jacobs corroborated these results, citing the initial January 1959 publication by Lejeune, Gautier, and Turpin.). The finding also established a link between intellectual disability and a chromosomal abnormality for the first time, and it helped launch cytogenetics as a discipline (The discovery opened up a new field of investigation for modern genetics and laid the foundation for a new discipline: cytogenetics.). Within a year, the researchers reported the first case of double aneuploidy, and later work showed that some familial cases arose from translocations and that partial trisomy could also produce the phenotype (A year later, Harnden et al. reported the first case of double aneuploidy (a boy with Trisomy 21 and Klinefelter syndrome); this was followed rapidly by the discovery that some familial cases of Trisomy 21 were caused by translocations). Because karyotyping could now reveal the chromosomal basis of the condition, the diagnosis moved from clinical impression toward laboratory confirmation.

Attitudes toward people with the condition and their institutional care also changed over the course of the twentieth century. In the late nineteenth century, care was often provided in large residential institutions. Down himself worked in this setting, having resigned from the Royal Earlswood Asylum in 1868 and then established a private home for people with developmental and intellectual disabilities at Normansfield, where the number of residents grew from 19 to 160 between 1868 and 1896 (This decision allowed Down to return to his full-time job at a London hospital and set up his own private home for those with developmental and intellectual disabilities at Normansfield. In 1868, when the House was established, 19 children lived in Normansfield, and in 1896 their number had grown to 160). Over the following decades, the prevailing model of large institutions was gradually questioned, and the move toward community-based living and education is discussed in later sections.

Epidemiology and global variation

Estimates of how often Down syndrome occurs depend heavily on what is counted and when. The most widely cited global figure is about 1 in 1,000 live births, and the United Nations World Down Syndrome Day materials put the worldwide incidence at roughly 1 in 1,000 to 1 in 1,100 live births, or about 3,000 to 5,000 babies a year. Figures for individual countries vary more. Secondary sources give United States estimates ranging from about 1 in 700 to about 1 in 1,400 births. Some of this spread reflects differences in case definitions, denominators and study years, rather than clear differences in underlying biology.

Two measures must be distinguished. Total prevalence counts all affected pregnancies that reach a set gestational age, including stillbirths and pregnancies ended after prenatal diagnosis. Live birth prevalence counts only infants who are born alive. Total prevalence is the closer measure of how often the chromosomal change arises, whereas live birth prevalence is strongly shaped by prenatal testing and legal policy. In the EUROCAT surveillance network, the total prevalence rose from 16 per 10,000 births in 1990 to 23 per 10,000 in 2015. In a EUROCAT analysis of 1990–2009 registrations covering 6.1 million births, average live birth prevalence was about 1 per 1,000, while a large share of recorded cases were terminations of pregnancy.

Maternal age is the main driver of total prevalence. Between 1980 and 1999, the proportion of European births to mothers aged 35 and over rose sharply in many regions, and total prevalence in 1995–1999 ranged from 1 to 3 per 1,000 births across regions. Within each maternal age group, the age-specific prevalence has stayed relatively constant, so a rising average age of childbearing alone pushes the overall rate upward. Prenatal screening and termination, however, have offset much of this effect on live birth prevalence in most European regions. Termination rates reported in the most recent available data include about 67% for the United States (1995–2011), 77% for France (2015) and 98% for Denmark (2015). Where screening uptake is very high, the numbers are dramatic: in Iceland, roughly 80 to 85% of pregnant women are screened, and only a handful of children with Down syndrome are born each year. Live birth prevalence in the Netherlands fell from 15.9 to 9.9 per 10,000 births between 2002 and 2018.

Differences between high-income and low-income countries have several causes. In Europe, the highest live birth prevalence has been recorded in Ireland, followed by Malta and Poland, all countries where termination is not available for this diagnosis. Screening uptake is also uneven within countries. Lower participation has been associated with lower socioeconomic status, and some studies report that antenatal diagnosis reached only about 15% of mothers in Ireland and the United Arab Emirates. In many middle- and low-income countries, a large share of women over 35 lack universal screening and diagnostic services. Surveillance infrastructure is a further constraint: many of these countries have few or no population-based registries, so published rates for them are often sparse, modelled or regionally limited, and cannot be directly compared with European figures.

Data sources and their limitations

Most prevalence figures come from population-based registries of congenital anomalies, such as the EUROCAT network, which records cases from registries covering a substantial part of European births, and national birth registries, such as the Dutch Perined database. Other data come from government birth certificates or health information systems. A Brazilian study of 2010–2020 live births, for example, relied on public government records and reported an average of about 30 per 100,000 live births, but such records are limited to those born alive and depend on accurate coding of the diagnosis.

Registries have several known weaknesses. Termination of pregnancy is often recorded differently across countries, or not recorded at all where it is illegal or unreported. Denominators (the total number of births) may be incomplete, and some registries cover only parts of a country. The EUROCAT analyses themselves attribute some regional differences to variations in reporting rather than in real occurrence. Validation studies have found that registration can be satisfactory in some settings and still leave gaps elsewhere. Comparisons across countries are therefore most reliable when they use the same case definitions, gestational cut-offs and time periods.

Trends over time

Long-term data show that total prevalence has generally risen while live birth prevalence has been more stable or falling. In a 20-year review of a malformation registry covering births from 1985 to 2004, total prevalence rose from 1.3 to 2.5 per 1,000 total births. Live birth prevalence declined during the first decade and increased during the second, so the overall change over the full period was negligible, even though total births fell by about 20%. Trends like these reflect demographic change, in particular the postponement of childbearing in many developed nations, together with the spread of prenatal diagnosis. Where screening programmes continue to expand, the gap between total and live birth prevalence is likely to widen further, which makes it especially important for future studies to report both measures clearly, along with prevalence and incidence definitions and the policy context.

Medical management and health surveillance

Routine health supervision

Care for people with Down syndrome is organized around scheduled health supervision rather than only responding to problems. The American Academy of Pediatrics (AAP) issues a clinical report on this, most recently updated in 2022, which sets out the examinations and screenings expected at each stage of childhood and adolescence. Clinicians are asked to plot growth on Down syndrome-specific charts, review feeding and iron intake in infancy, and check thyroid function periodically, since hypothyroidism is common in this population. Hearing and vision assessments are scheduled so that problems are found before they interfere with speech, language, and learning. The AAP also recommends a sleep study for every child, generally by about age four, because obstructive sleep apnea is frequent and is often hard to recognize by observation alone.

Following these schedules in practice is uneven. A 2025 review of records from a tertiary center in Colombia, which assessed adherence to the earlier 2011 guideline, found overall adherence of 57%. Echocardiograms and early karyotyping were usually done, but hearing and eye evaluations by six months were completed for only 60% and 34% of children, respectively. The authors linked these gaps to barriers in health care delivery, a concern that is relevant to any health-system.

Cardiac and gastrointestinal surgery

Congenital heart disease occurs in roughly half of newborns with Down syndrome, and the atrioventricular septal defect is the most common form. The AAP recommends that every infant with Down syndrome be evaluated by a pediatric cardiologist within the first month of life, partly because the surgical window for the most common defects is in the first year. Timing depends on the lesion. Repair of atrioventricular septal defects is usually planned for the first half-year, because prolonged high pulmonary blood flow can damage the lung vessels. Infants with severe symptoms such as fast breathing, poor feeding, or poor weight gain may need earlier operation, and some require temporary procedures to stabilize pulmonary circulation before definitive repair. Outcomes for complete repair of atrioventricular septal defects are generally excellent when care is delivered in experienced centers.

Gastrointestinal anomalies, including duodenal atresia and Hirschsprung disease, usually need surgical management in the newborn period and are assessed alongside cardiac findings. Children with Down syndrome may also have kidney or urinary tract differences that raise the risk of kidney injury after cardiac surgery, so perioperative planning typically accounts for both cardiac and noncardiac conditions. Careful assessment for pulmonary hypertension is also part of surgical planning.

Preventive care and infection

Children with Down syndrome are prone to recurrent respiratory infections, pneumonia, and ear infections. These problems are often compounded by airway narrowing, feeding difficulties that can lead to aspiration, and underlying heart or lung disease. Routine immunization according to the national schedule is recommended, along with seasonal influenza vaccination and attention to vaccines that protect against infections affecting the lungs. Monitoring for infection is usually integrated into regular visits, and clinicians are advised to investigate persistent respiratory symptoms, feeding problems, or weight loss promptly rather than attributing them to the syndrome.

Atlantoaxial instability and activity restrictions

Atlantoaxial instability, a looseness of the joint between the first and second cervical vertebrae, is reported in roughly 7% to 27% of people with Down syndrome, depending on the study and the diagnostic threshold used. Current US pediatric and adult guidelines recommend regular clinical assessment for neck or neurological symptoms, and they do not recommend routine neck X-rays for people without symptoms. This represents a shift from earlier practice. A 1984 AAP statement, linked to Special Olympics requirements, endorsed lateral neck radiographs and restricted athletes with a detected gap from certain sports. The AAP Committee on Sports Medicine later revisited this position in 1995, concluding that the value of routine radiographic screening was uncertain.

Thresholds used in practice vary. Some sources consider sports restriction when the gap exceeds about 4.5 mm and surgical stabilization when it exceeds about 10 mm, while Special Olympics rules and some clinical guidance still conflict. A randomized study of 91 children and young adults with asymptomatic instability found no differences in motor function, neurological signs, or atlantoaxial distance between those who continued usual sport and those who avoided riskier activities for a year. Adult guidance also stresses that unnecessary restriction carries its own physical and psychological costs. Whatever the approach, clinicians recommend precautions to protect the neck during anesthesia for every person with Down syndrome.

Gaps in the evidence

Much of the recommended practice rests on observational data, expert consensus, and small studies. Few large randomized trials have compared screening intervals, the benefit of treating sleep apnea, or the value of universal celiac testing; the AAP has advised heightened awareness of symptoms rather than routine evaluation of every child. Guidance also differs across countries and between pediatric and adult bodies, and adherence studies suggest that even well-established recommendations are not consistently implemented. Future work will need to address how these measures change long-term health, function, and quality of life, and how evidence-based schedules can be delivered in different health systems.

Early intervention, education, and inclusion

Early intervention for speech, language, and motor skills

Most people with Down syndrome show some degree of speech and language difficulty, and these problems are often the focus of early support. There are currently no standard interventions for improving the language skills of children with Down syndrome under the age of 36 months. A systematic review of early studies in children under six, covering eleven studies and 242 children, found that most reported positive effects on speech and language, but they are hampered by methodological issues and risk of bias. Parent-based approaches are among the more promising options, and the earlier an intervention is delivered, the better the language outcomes, according to the broader evidence on early intervention.

Motor and language development are closely connected in this population. A scoping review of motor–language links found that gains in motor skills are linked to gains in language skills in children with DS. For this reason, the review's authors argue that motor programmes should aim at promoting infants' interactions with objects and people in larger family and societal contexts. Direct evidence on motor outcomes is still limited. One small cohort study reported that infants who began structured tummy time before 11 weeks reached motor milestones earlier than those who did not. Earlier reviews of the field were less encouraging: they described consistency of short-term benefits in some areas, alongside conflicting evidence for gross motor, linguistic, and cognitive gains.

Feeding and oral-motor difficulties also receive attention. Behavioural interventions aimed at tongue posture and the development of jaw, lip, and tongue movements used in eating, drinking, and speaking are recommended, although the supporting evidence is rated as low-level.

Inclusive education and school type

The choice between mainstream and special schooling is among the most debated decisions for families. The best-known comparison, reported by Buckley and colleagues in 2000, followed teenagers of similar ability and family background. The teenagers who had been fully included in mainstream classes showed gains of more than 2 years in spoken language skills and 3 years in reading and writing ability on standardised measures. These gains were associated with 25-30 hours of additional learning support assistance. The same study found no differences in personal independence or social contacts out of school between the two groups.

Systematic evidence is thinner than the observational literature suggests. A recent systematic review identified three studies comparing education, health, social, and self-care outcomes among adolescents with Down syndrome who attended either mainstream or special secondary school. Two studies reported improved education outcomes among adolescents in mainstream secondary school, but both studies were subject to bias and limited generalizability, and no studies reported health outcomes. Attitudes among educators are also mixed. In one study, the majority of teachers are positive about the inclusion of children with Down's syndrome, yet around half were found to be neutral or have a preference towards children with Down's syndrome attending special educational settings. A UK parent and educator survey found that 70% of pupils attended mainstream placements but the proportion of children in specialist settings increased at older ages.

Support for adolescents and transition

Secondary school is where the gap between placement options is most often discussed, and where planning for life after school begins. Transition planning generally covers further education, vocational training, and the adult services a young person may need, but the sources reviewed here offer little detailed evidence on which vocational approaches work best. The systematic review noted above is a useful reminder that outcomes beyond education, including health and self-care, remain poorly studied.

Assistive technology and augmentative communication

Augmentative and alternative communication (AAC) is an umbrella term: any communication device, strategy, or system that supports or replaces natural spoken speech. Low-technology options include communication books or boards (non-powered), written words on paper, photographs, line drawings and pictograms. High-technology options include voice output communication aids (VOCAs), which are known as 'speech-generating devices' in North America.

The rationale for AAC rests on a pattern of strengths and weaknesses. Receptive language is often better than expressive language in individuals with Down syndrome. That is, people with Down syndrome often understand a LOT more than they can express. Because speech development often lags behind language development, children who use sign language or another form of augmentative and alternative communication such as a communication app can often express complex ideas with whole sentences. The Down Syndrome Resource Foundation advocates for the use of augmentative and alternative communication (AAC) along with speech practice.

The research base for AAC is encouraging but small. A systematic review found that two studies investigating the use of a sign language system (MAKATON) in children with Down syndrome reported improvements in language development. Three studies of the Picture Exchange Communication System reported improvements in language and social communication. Four studies investigating the use of speech-generating devices (SGDs) in children with Down syndrome reported improved communication in the domains of speech, cognition, and socializing. Those studies used designs ranging from clinical trials to case reports, so the strength of the conclusions is limited.

Life expectancy, adulthood, and family life

Rising life expectancy

Survival for people with Down syndrome has changed dramatically within about a century. One widely cited estimate puts average life expectancy near nine years in 1900, rising to around 28 years in the early 1980s and roughly 60 years in the United States today. Figures vary with the statistic used. For a baby born in the United States, the median rose from about four years in 1950 to 58 years in the 2010s. Much of this gain is credited to advances in cardiac surgery and in general health management. Fewer children are institutionalized and routine medical examinations have become standard, and both have also contributed to the increase. Improvement has not been uniform. In 2010, the median life expectancy for non-Hispanic Black and American Indian/Alaska Native people with the condition was 57 years, compared with 58 years for other groups, and the gap appears to be narrowing. Some researchers now suggest that progress may be slowing, because Alzheimer's disease has become a leading cause of mortality in this population.

Adulthood, work, and independent living

As survival has improved, adults now make up a growing share of the population. More than 216,000 Americans are living with the condition today, compared with fewer than 50,000 in 1950. Employment remains limited. A 2015 national survey in the United States found that 57% of adults with Down syndrome were employed, but only 3% had full-time paid employment, with most working in limited job categories. A later scoping review reported a recent employment rate of 53%, while noting that jobs are often limited to sectors like food service and are underutilizing their skills. Cognitive ability, family support, and social attitudes all appear to influence whether a person works . Estimates from different studies are not directly comparable because they use different samples and definitions.

Living arrangements show similar variation. While many adults with Down syndrome do move to independent living facilities before their parents die, more do not, because everyone feels this gives them the best quality of life or because a suitable alternative does not exist. Support organizations report that an increasing number of adults with Down syndrome in the U.S. are living independently with limited assistance from family members or the state, although a small percentage are able to live entirely independently. Parents also differ in how they define adulthood. For some it is marked by age, while for others it reflects emotional, mental, or physical maturity .

Choice, relationships, and rights

Surveys of adults with Down syndrome show consistent priorities. Most adults with Down syndrome wanted to become more independent, have relationships, participate in the community, and exercise their human rights. Self-reported quality of life tends to be rated higher than quality of life reported by proxies, which underlines the value of asking the adult directly . Research on self-determination treats choice-making as a critical first step toward autonomous functioning. The literature on partnerships and parenthood among adults with Down syndrome is comparatively thin, so this section does not draw firm conclusions about those areas. Legal frameworks on decision-making and rights are discussed elsewhere in this article.

Family caregiving

Families often provide support throughout the person's life. Family caregivers of adults with Down syndrome often provide life-long caregiving support for their loved one. In a qualitative study of 17 caregivers, most of whom were women with a mean age near 59, caregiving was described as constant, and four major themes emerged, including future planning and the importance of social supports. The same study concluded that trusted options for transportation services, life transition planning and respite care are needed.

Costs and income are a major concern. Caregivers give up work to take care of their children, resulting in reduced family income and difficulty in paying high medical expenses. Worry about the future is also common, particularly about how their child would be supported with the cost of medical care, housing, and other expenses. Medical complications add to the strain; managing associated medical concerns, such as heart defects, added to caregiver stress.

Aging and coordinated care

Aging brings new needs that span medical and social services. Some researchers link the extra copy of chromosome 21 to accelerated aging, though this remains an area of active study. Alzheimer's disease occurs at a higher rate and at a younger age in people with Down syndrome, which is discussed in more detail elsewhere. Many health services were designed for children and have been slow to adjust, and one account notes that aging adults with Down syndrome face a health system unprepared to care for them. Effective care therefore depends on coordination between clinicians, social services, and families, combining routine health monitoring with planning for housing, employment, and support as the person ages.

Research frontiers and experimental treatments

Silencing the extra chromosome in cell models

Because the extra copy of chromosome 21 underlies the condition, one line of research asks whether it can be switched off in cultured cells. In one approach, researchers used genome editing to place a large inducible XIST transgene onto one of the three chromosome 21 copies in patient-derived stem cells. The inserted gene brought transcription from the trisomic chromosome close to two-copy levels through heterochromatin formation and DNA methylation, and the repression was allele-specific, meaning it acted on the targeted chromosome rather than on the others. XIST-mediated silencing also normalised the production of other haematopoietic progenitors, and a newer inducible design was reported to produce near-complete and irreversible dosage correction in pluripotent cells. Phased allelic expression analysis showed the new design enables uniform, near-complete and irreversible T21 dosage correction.

The effects differ by cell type. In astrocyte precursor cells, silencing lowered the expression of most chromosome 21 genes and normalised their excessive growth, but that growth returned when XIST induction was stopped, and the team identified DYRK1A, DSCR3 and PIGP as candidate genes responsible for APCs overproliferation in DS. In neural cells, XIST RNA induced in differentiated neural cells can trigger chromosome-wide silencing of chromosome 21 in Down syndrome patient-derived cells. This revealed a deficiency in differentiation of trisomic neural stem cells to neurons, correctible by inducing XIST at different stages of neurogenesis. In blood-forming cultures, silencing corrected over-production of megakaryocytes and erythrocytes, key to DS myeloproliferative disorder and leukemia.

Single-cell methods have also shaped this work. Single-cell transcriptomics and other analyses strongly implicate elevated Notch signaling due to trisomy 21, thereby promoting neural stem cell cycling that delays terminal differentiation. Reviewers present such systems mainly as experimental tools for dissecting trisomy 21 biology, which could inform future drugs or gene therapies, rather than as a near-term clinical option.

Pharmacological trials aimed at cognition

Drug trials for cognitive function have so far produced little consistent benefit. A Cochrane review found that only nine studies (427 participants) met the inclusion criteria. For donepezil, scores in measures of cognitive functioning and measures of behaviour were similar to those who received placebo. Memantine likewise showed no clear difference from placebo in the reviewed studies. A later 16-week, randomised, double-blind, placebo-controlled, phase 2 trial in 160 adolescents and young adults found that memantine (10 mg twice a day) was well tolerated, but no benefit on hippocampal-dependent memory function was seen. A trial of a GABA-A modulator also showed no effect. A phase 2 trial of EGCG, which antagonises DYRK1A, a kinase encoded by a gene located on a region of chromosome 21 thought to contribute to intellectual disability, reported improvement in a visual memory test relative to placebo. This finding has not yet been widely replicated.

Several explanations are offered for the weak results. Many trials were small and underpowered; one commentary notes that overall, these treatments were considered ineffective, and the trials were hampered by low power. Drug levels were also an issue: in the memantine trial, plasma concentrations were subtherapeutic in most participants. Outcome measures are another constraint. A later meta-analysis reported that donepezil showed significant cognitive and behavioral improvements in individuals with DS, especially with longer treatment periods, which conflicts with the earlier Cochrane conclusions and shows that the evidence remains unsettled.

Trials for preventing early-onset Alzheimer's disease

Adults with Down syndrome are an important population for Alzheimer's disease prevention research, but they have been largely absent from trials of amyloid-targeting drugs. Individuals with DS are currently excluded from clinical trials of Aβ-targeting drugs, in part because of their comorbid intellectual impairment and other comorbidities, but also because until recently there has been a lack of biomarker data and validated measures of clinical progression in this population. Recent work has tried to fill these gaps. One study concluded that people with Down syndrome typically develop Alzheimer's disease neuropathology before age 40, and suggested that varied treatment effects could be detected with 50-200 people per arm when using sensitive cognitive outcome measures and targeting recruitment to ages 36 to 45 years. Another analysis disagreed on timing, finding that significant decline over a 2- to 3-year period for a prospective placebo group of adults with Down syndrome enrolled in clinical prevention trials can only be expected when inclusion is limited to adults older than 45 years of age.

Infrastructure for such trials is being built. The Trial-Ready Cohort for Down Syndrome will enroll people with Down syndrome who have no symptoms of dementia to participate in future Alzheimer's disease prevention studies. A European consortium is also developing a clinical trials network and feasible and acceptable protocols for such trials.

Methodological and ethical challenges

Trials in this population face problems that go beyond the biology. Samples have often been small, and outcome measures must be sensitive enough to detect change in people with baseline intellectual disability, while also being feasible to administer. Test batteries have been evaluated for reliability across sites, and a few measures, however, were deemed unsuitable for use in future studies. Ethical questions include how consent is obtained and how participants' own wishes are represented, and how to balance early enrolment, when risk of decline is still low, against the burden of participation.

Rights, language, and social perspectives

Rights for people with Down syndrome are largely covered by the wider disability-rights framework, and the most consequential instrument is the United Nations Convention on the Rights of Persons with Disabilities. Scholars describe its Article 24 as the first legal recognition of inclusive education as a right for people with disabilities, and Article 24 of the United Nations Convention on the Rights of Persons with Disabilities (UNCRPD) contains the first legal enshrinement of the right to inclusive education for people with disabilities. The article asks governments to build an inclusive school system at every level, and reasonable accommodation is to be provided to persons with disabilities. Critics argue that a fully inclusive model may not serve every child's interests, and that the moral right to receive the education most appropriate to one's needs can conflict with mainstreaming. The convention therefore shapes education policy and human rights claims for people with Down syndrome, but its effect depends on national legislation and on resources.

Stigma has been as consequential as the medical facts. The older name "mongolism" rested on the idea that people with the condition looked like Mongolians, a belief that individuals with Down syndrome, with their wide-set eyes and round faces, resembled Mongolians. The physical traits used to define the condition were erroneously linked to racial groups before a chromosomal definition replaced them. The term has since been dropped from medical use and is deemed unacceptable, offensive and a slur. The change was driven by scientific and medical experts, as well as people of Asian ancestry, including those from Mongolia. Negative attitudes still shape opportunities; advocates note that people with Down syndrome are often excluded from parts of society, and the theme of World Down Syndrome Day in 2022 asked what inclusion actually means in practice.

Language conventions reflect the same concern. Person-first wording, which puts the "person" before the "disability", is the most widely recommended style, so one speaks of a child with Down syndrome rather than a Down syndrome child. Guidance also advises that phrases such as "suffers from," "is afflicted with," or "is a victim of" are discouraged. Terminology has changed in official use as well: the United States government, American medical and psychiatric professionals, and the World Health Organization no longer use the term "mental retardation," and instead use the term "intellectual disability." Some critics find person-first constructions awkward in English, and argue that they can highlight the disability in an unhelpful way.

World Down Syndrome Day on 21 March was chosen to point to the three copies of chromosome 21 that cause the condition, since the date, 3/21, symbolizes the triplication of the 21st chromosome. The day was first launched in Singapore in 2006. Sources differ on the date of formal UN recognition: one states that the date was made official by the United Nations General Assembly in 2011, while others say the UN has observed it since 2012. The 2026 theme, "Together Against Loneliness," stresses connection and inclusion.

Advocacy is carried out by families, national associations and international networks. The day is coordinated by Down Syndrome International (DSi), a global advocacy organization working to improve the quality of life for individuals with Down syndrome worldwide. Self-advocacy groups, in which adults with Down syndrome speak for themselves in public campaigns and consultations, have grown in influence. Advocates have argued that people with the condition should help set research questions and policy priorities, rather than serving only as subjects of study.

References

1. Down Syndromelink.springer.com
2. Understanding the genetic mechanisms and cognitive impairments in Down syndrome: towards a holistic approachncbi.nlm.nih.gov
3. Down Syndrome: Practice Essentials, Background, Pathophysiologyemedicine.medscape.com
4. Down Syndrome (Trisomy 21) - Pediatrics - Merck Manual Professional Editionmerckmanuals.com
5. Trisomy 21 - an overviewsciencedirect.com
6. Down syndromemedlink.com
7. Down Syndrome (Trisomy 21) - Children's Health - MSD Manual Consumer Versionmsdmanuals.com
8. Methods for identifying chromosomal aneuploidyimage-ppubs.uspto.gov
9. Trisomy 21/Down Syndrome - EyeWikieyewiki.org
10. Down Syndromekennedykrieger.org
11. Down syndrome - PubMed - NIHpubmed.ncbi.nlm.nih.gov
12. International Mosaic Down Syndrome Association - mDs Studiesimdsa.org
13. What Is Down Syndrome (Trisomy 21)?my.clevelandclinic.org
14. Down Syndrome due to de Novo Robertsonian Translocation Rob(21;21) in Mali - Ongoiba - 2026 - Clinical Case Reports - Wiley Online Libraryonlinelibrary.wiley.com
15. Robertsonian Chromosome Translocation - an overviewsciencedirect.com
16. Robertsonian Translocation - an overviewsciencedirect.com
17. Robertsonian Translocation t (21; 21) Offspring of a Balanced Translocation Carrier Parent; an Unfortunate Scenariojournals.lww.com
18. Down Syndrome Genetics: The 3 Main Typesincitefulmed.com
19. Partial trisomy 21 with or without highly restricted Down syndrome critical region (HR-DSCR): report of two new cases and reanalysis of the genotype–phenotype associationbmcmedgenomics.biomedcentral.com
20. Partial trisomy 21link.springer.com
21. A patient with partial trisomy 21 and 7q deletion expresses mild Down syndrome phenotype - ScienceDirectsciencedirect.com
22. Systematic reanalysis of partial trisomy 21 cases with or without Down syndrome suggests a small region on 21q22.13 as critical to the phenotypeacademic.oup.com
23. Understanding Trisomy 21, Mosaicism, and Translocation - GiGis Playhousegigisplayhouse.org
24. Types of Down Syndrome - CMDSScmdss.org
25. Translocation Down (Trisomy 21) Syndromecontemporarypediatrics.com
26. Robertsonian Translocation in a Down Syndrome: A Case Reportarticle.sapub.org
27. What are the risk factors for having a child with Down syndrome?droracle.ai
28. What Causes Down Syndrome?intechopen.com
29. Nondisjunction and aneuploidyebsco.com
30. The etiology of Down syndrome: Maternal MCM9 polymorphisms increase risk of reduced recombination and nondisjunction of chromosome 21 during meiosis I within oocytejournals.plos.org
31. Etiology of Down Syndrome: Risk of Advanced Maternal Age and Altered Meiotic Recombination for Chromosome 21 Nondisjunctionintechopen.com
32. Risk Factors for Down Syndrome Birth: Understanding the Causes from Genetics and Epidemiologyintechopen.com
33. Studies of Association of Environmental Risk Factors in Down Syndrome - D-Scholarship@Pittd-scholarship.pitt.edu
34. The Multifactorial Causes of Down Syndrome During Pregnancy: A Narrative Review of Genetic, Environmental, and Maternal Influencesncbi.nlm.nih.gov
35. New Insights into Human Nondisjunction of Chromosome 21 in Oocytesncbi.nlm.nih.gov
36. Robertsonian translocation Down syndrome: when parental karyotypes make the differencescielo.org.pe
37. Robertsonian translocations: what to do? - Breda Genetics srlbredagenetics.com
38. Population monitoring of trisomy 21: problems and approachesncbi.nlm.nih.gov
39. Robertsonian Translocation t (21; 21) Offspring of a Balanced Translocation Carrier Parent; an Unfortunate Scenarioovid.com
40. Molecular Pathways of Down Syndrome Critical Region Genesintechopen.com
41. Down syndrome phenotype in a boy with a mosaic microduplication of chromosome 21q22link.springer.com
42. Microdeletion of the Down syndrome critical region at 21q22 - PubMedpubmed.ncbi.nlm.nih.gov
43. Frontiersfrontiersin.org
44. Interplay between DYRK1A dosage and aneuploidy-induced neuropathology in Down syndrome - PMCpmc.ncbi.nlm.nih.gov
45. Congenital heart defects in Down syndrome are caused by increased dosage of DYRK1Abiorxiv.org
46. Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2Dncbi.nlm.nih.gov
47. Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes - PMCpmc.ncbi.nlm.nih.gov
48. The genome-wide impact of trisomy 21 on DNA methylation and its implications for hematopoiesisnature.com
49. Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression: Cell Reportscell.com
50. Aberrant chromatin remodeling influences human neural cell fate change in Trisomy 21 - PMCpmc.ncbi.nlm.nih.gov
51. Trisomy 21 Alters DNA Methylation in Parent-of-Origin-Dependent and -Independent Mannersncbi.nlm.nih.gov
52. Dosage compensating transgenes and cellsimage-ppubs.uspto.gov
53. DNA-Methylation Patterns in Trisomy 21 Using Cells from Monozygotic Twinsjournals.plos.org
54. Down Syndromeposna.org
55. Down Syndrome - OrthoPaediaorthopaedia.com
56. Down Syndrome Clinical Presentation: History, Physical Examination, Complicationsemedicine.medscape.com
57. Orthopaedic Management in Down Syndrome - ScienceDirectsciencedirect.com
58. Musculoskeletal anomalies in children with Down syndrome: an observational study - PMCpmc.ncbi.nlm.nih.gov
59. Down Syndrome: Musculoskeletal Effects - OrthoInfo - AAOSorthoinfo.org
60. Heart Malformations in Children With Down Syndrome - Revista Española de Cardiología (English Edition)revespcardiol.org
61. Atrial Septal Defect with Down Syndrome and Postsurgical Pulmonary Hypertension - PMCpmc.ncbi.nlm.nih.gov
62. Congenital heart disease and Down syndrome: various aspects of a confirmed association - PMCpmc.ncbi.nlm.nih.gov
63. Identifying genetic factors that contribute to the increased risk of congenital heart defects in infants with Down syndromenature.com
64. Congenital gastrointestinal defects in Down syndrome: a report from the Atlanta and National Down Syndrome Projects - PMCpmc.ncbi.nlm.nih.gov
65. JCI Insight - Down syndrome mouse models have an abnormal enteric nervous systeminsight.jci.org
66. Concomitant Duodenal Atresia and Hirschsprung Diseasefacs.org
67. Duodenal atresiaen.wikipedia.org
68. Health Supervision for Children and Adolescents With Down Syndromepublications.aap.org
69. Health Supervision for Children With Down Syndromepublications.aap.org
70. Health Care Management of Adults with Down Syndromeaafp.org
71. Guideline for Medical Management of Childrenplatform.who.int
72. Atlantoaxial Instability in Down Syndrome: Background, Epidemiology, Anatomyemedicine.medscape.com
73. Atlantoaxial Instability in Children with Down Syndrome - HealthyChildren.orghealthychildren.org
74. Atlantoaxial Instability in Down Syndrome Clinical Presentation: History, Physical Examinationemedicine.medscape.com
75. Health and disease in adults with Down syndrome - PubMedpubmed.ncbi.nlm.nih.gov
76. Transient abnormal myelopoiesis (TAM) of Down syndrome (DS) - UpToDateuptodate.com
77. Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemiancbi.nlm.nih.gov
78. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome - PubMedpubmed.ncbi.nlm.nih.gov
79. Transient Abnormal Myelopoiesis: An Abnormal Course and the Efficacy of Delayed Treatmentncbi.nlm.nih.gov
80. 2020 Written by the Global Down Syndrome Foundation Medical Care Guidelinesdsacc.org
81. Down syndrome and leukemia: from basic mechanisms to clinical advanceshaematologica.org
82. Cognitive profiles in children and adolescents with Down syndromenature.com
83. The Down Syndrome Profile Emerges Gradually Across Early Development - PMCpmc.ncbi.nlm.nih.gov
84. Individuals with Down Syndrome: Editorial - PMCpmc.ncbi.nlm.nih.gov
85. Down Syndrome: Neuropsychological Phenotype across the Lifespanncbi.nlm.nih.gov
86. Capturing cognitive and behavioral variability among individuals with Down syndrome: a latent profile analysislink.springer.com
87. On the Design of Broad-Based Neuropsychological Test Batteries to Assess the Cognitive Abilities of Individuals with Down Syndrome in the Context of Clinical Trialsncbi.nlm.nih.gov
88. Cognitive profiles in individuals with Down syndrome - ScienceDirectsciencedirect.com
89. The association between expressive language skills and adaptive behavior in individuals with Down syndromencbi.nlm.nih.gov
90. Language and verbal short-term memory skills in children with Down syndrome: A meta-analytic review - ScienceDirectsciencedirect.com
91. Language, cognition, and short-term memory in individuals with Down syndromedown-syndrome.org
92. Morphosyntactic development in German-speaking individuals with Down syndrome—longitudinal datancbi.nlm.nih.gov
93. Psychopathology in Down Syndromeintechopen.com
94. Associations of Down Syndrome with Autism Spectrum Disorder and Attention Deficit/ Hyperactivity Disorder Among Children and Adolescents - PMCpmc.ncbi.nlm.nih.gov
95. Prevalence of autism and attention‐deficit–hyperactivity disorder in Down syndrome: a population‐based study - Oxelgren - 2017 - Developmental Medicine & Child Neurology - Wiley Online Libraryonlinelibrary.wiley.com
96. Health comorbidities and cognitive abilities across the lifespan in Down syndrome - PMCpmc.ncbi.nlm.nih.gov
97. Mental Health and Treatment in Down Syndromecareds.org
98. Mental Health & Down Syndromendss.org
99. Alzheimer's Disease Amyloid-β Links Lens and Brain Pathology in Down Syndromencbi.nlm.nih.gov
100. Unclassifiable senile plaques and extensive cerebral amyloid angiopathy involving spinal and bridging vessels in autopsied patients with Down syndrome - PMCpmc.ncbi.nlm.nih.gov
101. Early age-related progression of AD-like neuropathology in Down's syndrome - PubMedpubmed.ncbi.nlm.nih.gov
102. Down syndrome and Alzheimer's diseasedementia.org.au
103. On the Therapeutic Use of Monoclonal Antibodies Against Amyloid Plaques in Older Adults with Down Syndrome: A Narrative Review and Perspectivencbi.nlm.nih.gov
104. Alzheimer's disease associated with Down syndrome: a genetic form of dementia - ScienceDirectsciencedirect.com
105. Down's syndrome and dementiacambridge.org
106. Down Syndrome and Dementia: What to Know - Penn Memory Centerpennmemorycenter.org
107. Development of Alzheimer’s disease in Down syndromeexplorationpub.com
108. β-Secretases, Alzheimer's Disease, and Down Syndromencbi.nlm.nih.gov
109. Alzheimer’s disease in people with Down’s syndrome: the prospects for and the challenges of developing preventative treatmentsncbi.nlm.nih.gov
110. Down Syndrome and Alzheimer'salz.org
111. The pattern of amyloid accumulation in the brains of adults with Down syndromencbi.nlm.nih.gov
112. Genetic Mapping of APP and Amyloid-β Biology Modulation by Trisomy 21jneurosci.org
113. Down Syndrome: Prenatal Risk Assessment and Diagnosisaafp.org
114. Down syndrome and neonatessafercare.vic.gov.au
115. Diagnosing a Genetic Disordernature.com
116. Down syndrome: Clinical features and diagnosis - UpToDateuptodate.com
117. After a Down Syndrome Diagnosis: Genetic Checkpoints3billion.io
118. International Mosaic Down Syndrome Association - Mosaic Down Syndromeimdsa.org
119. International Mosaic Down Syndrome Association - How to get a diagnosesimdsa.org
120. What Is Mosaic Down Syndrome: Symptoms and Diagnosis - Biology Insightsbiologyinsights.com
121. Comprehensive Cytogenetic Analysis Reveals Mosaicism in Newborn with Negative Prenatal Down Syndrome Screening: A Case Report - PMCpmc.ncbi.nlm.nih.gov
122. FISH Analysis - Prenatal Aneuploidycatalog.baylorgenetics.com
123. Biomarkers for the detection and screening of down syndromeimage-ppubs.uspto.gov
124. Assessment of Women's Insight and Understanding of Down's Syndrome Screening by Non-invasive Prenatal Testing (NIPT) During Their First Ultrasoundclinicaltrials.gov
125. Down Syndrome Tests: MedlinePlus Medical Testmedlineplus.gov
126. Prenatal Genetic Screening Testsacog.org
127. Noninvasive Prenatal Fetal Screening Tests - Gynecology and Obstetrics - Merck Manual Professional Editionmerckmanuals.com
128. Cell-Free Fetal DNA and Non-Invasive Prenatal Diagnosis of Chromosomopathies and Pediatric Monogenic Diseases: A Critical Appraisal and Medicolegal Remarks - PMCpmc.ncbi.nlm.nih.gov
129. Cell-free DNA Screening (cfDNA)unchealth.org
130. Prenatal Genetic Testingnm.org
131. Cell-free DNA Analysis for Noninvasive Examination of Trisomynejm.org
132. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis - PMCpmc.ncbi.nlm.nih.gov
133. Prenatal cell-free DNA screening test failures: a systematic review of failure rates, risks of Down syndrome, and impact of repeat testing - ScienceDirectsciencedirect.com
134. Termination of pregnancy following a prenatal diagnosis of Down syndrome: A qualitative study of the decision-making process of pregnant couples - PubMedpubmed.ncbi.nlm.nih.gov
135. In Iceland, almost all diagnosed Down syndrome pregnancies are aborted after prenatal testing. Some bioethics experts are concerned - ABC Newsabc.net.au
136. 20 Countries With Highest Rate Of Down Syndromefinance.yahoo.com
137. Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndromencbi.nlm.nih.gov
138. Neonatal mortality and morbidity in Down syndrome in the time of prenatal aneuploidy testing: a retrospective cohort studyncbi.nlm.nih.gov
139. Has noninvasive prenatal testing impacted termination of pregnancy and live birth rates of infants with Down syndrome?ncbi.nlm.nih.gov
140. Assessment of a Simplified Cell-Free DNA Method for Prenatal Down Syndrome Screeningacademic.oup.com
141. The 50th anniversary of the discovery of trisomy 21: The past, present, and future of research and treatment of Down syndromenature.com
142. History of Down syndrome - wikidocwikidoc.org
143. (PDF) Dr Langdon Down (1828-1896) and 'mongolism'researchgate.net
144. John Langdon Downen.wikipedia.org
145. The Offensive Past of the Term Used for Down Syndromepsychologytoday.com
146. The 50th anniversary of the discovery of trisomy 21: The past, present, and future of research and treatment of Down syndrome - Genetics in Medicinegimjournal.org
147. Who was professor jerôme Lejeune? - Institut Lejeuneinstitutlejeune.org
148. Jérôme Lejeune (1926−1994)embryo.asu.edu
149. Fiftieth anniversary of trisomy 21: Returning to a discoveryresearchgate.net
150. J%C3%A9r%C3%B4me Lejeuneen.wikipedia.org
151. John Langdon Haydon Down (1828–1896)ncbi.nlm.nih.gov
152. Mongolism in Orientalsjamanetwork.com
153. Mongolian idiocyen.wikipedia.org
154. How did Down syndrome get its name? « # « Cambridge Core Blogcambridge.org
155. 1959: Chromosome Abnormalities Identifiedgenome.gov
156. Twenty-year trends in prevalence and survival of Down syndromenature.com
157. World Down Syndrome Dayun.org
158. Down Syndrome Statistics by Country (Top 8) in 2025doctorsolve.com
159. Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screeningnature.com
160. Trends and geographic inequalities in the prevalence of Down syndrome in Europe, 1980-1999 - PubMedpubmed.ncbi.nlm.nih.gov
161. EUROCAT - Surveillance of congenital anomalies in Europe: epidemiology of Down syndrome 1990 - 2014publications.jrc.ec.europa.eu
162. EUROCAT Special Report: Geographic Inequalities in Public ...eu-rd-platform.jrc.ec.europa.eu
163. Declining birth rates of children with Downs Syndrome in the Nordic countries - United Nations Western Europeunric.org
164. "What kind of society do you want to live in?": Inside the country where Down syndrome is disappearingcbsnews.com
165. Frontiersfrontiersin.org
166. Follow-up of a 10-year period (2010-2020) of Down syndrome in Brazilncbi.nlm.nih.gov
167. Socio-economic regional microscope series EUROCATpublications.jrc.ec.europa.eu
168. Health Supervision for Children and Adolescents With ...dsacf.org
169. American Academy of Pediatrics & Global Down Syndrome Foundation Collaborate on Down Syndrome Recommendations - Global Down Syndrome Foundationglobaldownsyndrome.org
170. Adherence to the American Academy of Pediatrics Health Supervision Guidelines for Children With Down Syndrome in a Tertiary Care Institution in Northeastern Colombiancbi.nlm.nih.gov
171. AAP Guidelines: Health Supervision of Down Syndrome Patientsmedscape.com
172. Health Care Information for Families of Children and ...childrenshospital.org
173. Atlantoaxial Instability (AAI) in People with Down Syndromeadscresources.advocatehealth.com
174. Atlanto-Axial Instability in People with Down’s Syndrome and its Impact on the Ability to Perform Sports Activitiespmc.ncbi.nlm.nih.gov
175. Atlantoaxial Instability in Down Syndrome: Controversy and Commentarydsagsl.org
176. Craniocervical Instability in Down Syndrome - Physiopediaphysio-pedia.com
177. Orthopedists Offer “Go-To” Guidance for Managing Down Syndromereports.mountsinai.org
178. SPECIAL OLYMPICS OFFICIAL POLICY AFFECTING ATHLETES WITH DOWN SYNDROMEspecialolympicswisconsin.org
179. Congenital Heart Defects and Down Syndrome:What Parents Should Know - Global Down Syndrome Foundationglobaldownsyndrome.org
180. Cardiovascular Complications of Down Syndrome: Scoping Review and Expert Consensusahajournals.org
181. The Heart & Down Syndromendss.org
182. Down syndrome and congenital heart disease: perioperative planning and managementncbi.nlm.nih.gov
183. Perioperative Acute Kidney Injury and Prognosis of Infants With Down Syndrome and Congenital Heart Diseasencbi.nlm.nih.gov
184. The ASCEND study: protocol for a feasibility study to evaluate an early social communication intervention for young children with Down syndromencbi.nlm.nih.gov
185. Motor-language links in children with Down syndrome: a scoping review to revisit the literature with a developmental cascades lens - PMCpmc.ncbi.nlm.nih.gov
186. Early intervention with children with Down syndrome - Past and future issuesdown-syndrome.org
187. Clinical Practice Guideline: Report of the Recommendations. Down Syndrome, Assessment and Intervention for Young Children (Age 0-3 Years)apps.asha.org
188. Inclusive education for individuals with Down syndromedown-syndrome.org
189. Mainstream or special secondary school for the health, education, and well‐being of adolescents with Down syndrome: A systematic review - PMCpmc.ncbi.nlm.nih.gov
190. Issues and perspectives on educationdown-syndrome.org
191. AAC - Down Syndrome Resource Foundationdsrf.org
192. Augmentative and alternative communication in children with Down’s syndrome: a systematic reviewncbi.nlm.nih.gov
193. Say What? Augmentative and Alternative Communication - Down Syndrome Resource Foundationdsrf.org
194. Speech - Down Syndrome Resource Foundationdsrf.org
195. Augmentative and Alternative Communication in Children With Down’s Syndrome: A Systematic Reviewapps.asha.org
196. Early Intervention for Infants with Down Syndrome - CentAURcentaur.reading.ac.uk
197. Applying Evidence-Based Interventions for a Child with Down Syndrome (Age 0–3 Years): A View Through the F-Words Lens Tool Frameworkdoi.org
198. Speech and language therapy for children with Down syndromelibrary.down-syndrome.org
199. Life Expectancy of Adults with Down Syndromeedhub.ama-assn.org
200. People With Down Syndrome Are Living Longer, but the Health System Still Treats Many as Kids - KFF Health Newskffhealthnews.org
201. Life Expectancy, Aging, and the Down Syndrome Populationadultdownsyndrome.org
202. Cancer and Post-therapy Cardiotoxicity Risk in Adolescents, Young Adults, and Adults with Down Syndromemedrxiv.org
203. Employment in Adults with Down Syndrome in the United States: Results from a National Surveyresearchgate.net
204. (PDF) Employment of people with Down syndrome: A scoping reviewresearchgate.net
205. Independence and employment for adults with Down syndromedown-syndrome.org
206. Down Syndrome Misconceptions vs. Reality - Global Down Syndrome Foundationglobaldownsyndrome.org
207. The meaning of adulthood for emerging adults with Down ...hands.fiu.edu
208. Employment and choice-making for adults with intellectual ...nisonger.osu.edu
209. Caregiving for Adults With Down Syndrome: Caregiver Experiences and Support Needs - PubMedpubmed.ncbi.nlm.nih.gov
210. Caregivers’ experience of having a child with Down syndrome: a meta-synthesisbmcnurs.biomedcentral.com
211. Stress and Coping among Family Caregivers of Children with Down Syndrome: a Meta-synthesis of Qualitative Researchlink.springer.com
212. Down Syndrome Life Expectancy Is Higher, But Not For Everyonenationwidechildrens.org
213. Life Expectancy of Adults with Down Syndromecareds.org
214. Silencing the extra chromosome 21 in Down syndrome cells - Fondation Lejeune Researchresearch.fondationlejeune.org
215. A dynamic *in vitro* model of Down Syndrome neurogenesis with Trisomy 21 gene dosage correctionbiorxiv.org
216. Silencing Trisomy 21 with XIST in Neural Stem Cells Promotes Neuronal Differentiation - ScienceDirectsciencedirect.com
217. Trisomy silencing by XIST normalizes Down syndrome cell pathogenesis demonstrated for hematopoietic defects in vitronature.com
218. Silencing Trisomy 21 with XIST in Neural Stem Cells Promotes Neuronal Differentiation - PubMedpubmed.ncbi.nlm.nih.gov
219. Pharmacological interventions for cognitive decline in people with Down syndrome - PubMedpubmed.ncbi.nlm.nih.gov
220. Development of treatments for Down syndrome - PMC - NIHpmc.ncbi.nlm.nih.gov
221. Pharmacotherapy in Down's syndrome: which way forward? - The Lancet Neurologythelancet.com
222. Full article: Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerationstandfonline.com
223. A meta‐analysis and systematic review of interventions to prevent or treat cognitive decline related to Alzheimer's disease in adults with Down syndromencbi.nlm.nih.gov
224. Alzheimer's disease in Down syndrome: An overlooked population for prevention trialsalz-journals.onlinelibrary.wiley.com
225. Optimal age and outcome measures for Alzheimer's disease prevention trials in people with Down syndrome - UCL Discoverydiscovery.ucl.ac.uk
226. Adults with Down syndrome in randomized clinical trials targeting prevention of Alzheimer's disease - PubMedpubmed.ncbi.nlm.nih.gov
227. Alzheimer's Clinical Trial Consortium for Down Syndrome (ACTC-DS) Trial-Ready Cohort - Down Syndrome (TRC-DS)alzheimers.gov
228. Baseline Neuropsychological Characteristics of Adolescents and Young Adults with Down Syndrome Who Participated in Two Clinical Trials of the Drug Memantinencbi.nlm.nih.gov
229. Trisomy silencing by XIST: translational prospects and challenges - PubMedpubmed.ncbi.nlm.nih.gov
230. Medications for cognitive decline in people with Down syndromecochrane.org
231. 5 advancements in Down syndrome research over the past yearlabiotech.eu
232. Will UN Article 24 lead to the demise of special education or to its re‐affirmation? - Hyatt - 2017 - Support for Learning - Wiley Online Librarynasenjournals.onlinelibrary.wiley.com
233. Convention on the Rights of Persons with Disabilitiesohchr.org
234. What People With Down's Syndrome Used to Be Calledtodayifoundout.com
235. Down Syndrome: The Evolution of Language and Identity Definition in Psychologyencyclopedia.arabpsychology.com
236. peoplefirst languagesk.sagepub.com
237. Understanding Down Syndrome - DSAWMdsawm.org
238. Recognizing World Down Syndrome Day on 3/21medicine.uky.edu
239. World Down Syndrome Day: Special meaning behind the March 21 datewwlp.com
240. World Down Syndrome Dayamdisrights.org
241. World Down Syndrome Day 3/21 - United Rehabilitation Services of Greater Daytonursdayton.org
242. Why World Down Syndrome Day Is Celebrated on March 21drnozebest.com
243. Article 24 - Educationsocial.desa.un.org
244. Language Guidelinesdsagws.org